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Cardiovascular risk in dialysis 
patients: an X-ray vision on 
vascular calcifications
Teresa Adragão1 and João M. Frazão2
In dialysis patients, there is an association between vascular 
calcifications and mortality. Hyperphosphatemia and calcium overload 
are associated with development of vascular calcifications, especially 
in the presence of low bone turnover. Different plain X-ray methods are 
now available to evaluate vascular calcifications in dialysis patients. 
The presence of vascular calcifications is an alert sign for increased 
cardiovascular risk, and this information is important for choosing the 
most suitable treatment for dialysis patients.
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Introduction
In recent years, observational studies in 
dialysis patients have verified the exist-
ence of an association between vascu-
lar calcifications and mortality.1–5 The 
abnormal mineral metabolism, a conse-
quence of chronic kidney disease (CKD), 
has been associated with development 
of vascular calcifications. In an in vitro 
model using smooth muscle cells from 
the human aorta, it was demonstrated 
that high levels of phosphorus, calcium, 
or both induce vascular calcification6 
by an active intracellular process that 
transforms vascular smooth muscle cells 
into osteoblast-like cells. Vascular cal-
cifications are associated with low bone 
turnover,7 and the hypothesis of the exist-
ence of a link between bone disease and 
cardiovascular disease has been raised. 
Kidney Disease: Improving Global Out-
comes (KDIGO) has recommended a new 
classification for chronic kidney disease 
mineral and bone disorder (CKD-MBD) 
that includes the presence of vascular 
calcifications.
Methods to evaluate  
vascular calcifications
Braun et al.,8 in 1996, used electron 
beam computed tomography to evaluate 
coronary calcifications and showed that 
hemodialysis patients had a very high 
coronary Agatston score when compared 
with nonrenal patients. Blacher et al.,1 
in 2001, demonstrated for the first time 
that the presence of vascular calcifica-
tions in hemodialysis patients, evaluated 
by ultrasonography in large arteries, was 
associated with increased mortality. In 
2003, London et al.2 showed that vascu-
lar calcifications evaluated in plain X-ray 
were associated with all-cause and cardi-
ovascular mortality in dialysis patients. 
After these initial observations, other 
studies3,5 confirmed the association 
between vascular calcifications, evalu-
ated with plain X-ray, and mortality in 
the CKD stage 5 hemodialysis popula-
tion. We developed a simple vascular 
calcification score, using the presence of 
vascular calcification, in a plain X-ray 
of the pelvis and hands3 (Figure 1). This 
simple score was an independent pre-
dictor of cardiovascular death, cardio-
vascular hospitalizations, and vascular 
disease in dialysis patients. The Kauppila 
score, using the presence of vascular cal-
cification in a plain X-ray of the lateral 
abdominal aorta, previously associated 
with cardiovascular death in the general 
population, has been recently validated 
for evaluating mortality risk in hemo-
dialysis patients (E. Honkanen et al., 
2008; EDTA Congress; Stockholm, Swe-
den; abstr.). Even a simpler evaluation of 
vascular calcifications in the abdominal 
aorta, identifying only the presence or 
absence of calcifications,5 was also a pre-
dictor of mortality in dialysis patients. 
Schlieper et al.9 (this issue) now publish 
an interesting observation showing that 
the presence of vascular calcification 
of the hemodialysis vascular access, 
evaluated by plain X-ray, is also an 
independent predictor of mortality.
Electron beam computed tomo graphy 
and multislice computed tomo graphy 
are considered the gold standard for 
quantitative evaluation of vascular cal-
cifications, but they are expensive and 
not widely available. In the setting of 
clinical trials performed with CKD 
patients, these quantitative techniques 
have been useful to evaluate the effect 
of different treatment options on vascu-
lar calcification progression. However, 
the meaning of the coronary Agatston 
score is different in dialysis patients as 
compared with the general population. 
In the general population, the coronary 
Agatston score is correlated with the 
atherosclerotic calcium load and is a 
predictor of cardiovascular events. In 
dialysis patients, there is no precise 
correlation between calcium score and 
coronary angiography. The Agatston 
score does not differentiate intimal from 
medial calcification, and hemodialysis 
patients can have a very high coronary 
Agatston score, because both intimal and 
medial calcifications may be present in 
coronary arteries. Medial calcifications 
contribute to aortic stiffness and to 
decreased coronary perfusion dur-
ing diastole without causing coronary 
stenotic lesions. For that reason, a high 
coronary Agatston score cannot be used 
to identify dialysis patients who will 
benefit from a coronary angioplasty.
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Vascular calcification evaluated  
in the vascular access
Schlieper et al.9 evaluated calcification of 
arteriovenous fistulas or synthetic grafts 
with plain X-ray and verified that cal-
cification of the vascular access was an 
independent predictor of mortality. The 
authors conclude that this is a cost-effective 
and easy-to-perform method to identify 
dialysis patients at increased mortality 
risk. Calcification of the vascular access 
was present in 23% of patients and was 
associated with male gender, diabetes, and 
dialysis vintage. The authors have verified 
that the presence of calcifications in the 
vascular access was highly correlated with 
the presence of vascular calcifications of 
iliac and femoral arteries, suggesting that 
there is a common pathogenic process 
affecting these different sites of the vascu-
lature. This common pathogenic process 
could explain why vascular calcifications, 
independently of their localization, are 
associated with mortality risk. The pres-
ence of calcification in the vascular access 
may have, however, a different mean-
ing from that observed in other arteries. 
Intimal calcification is associated with 
atherosclerotic plaques, and medial calci-
fication is associated with arteriolosclero-
sis. In hemodialysis patients it has already 
been demonstrated2 that these two types 
of vascular calcifications may coexist in 
the same patient and in the same vessel 
and that they are independent predictors 
of cardiovascular and all-cause mortality. 
Calcification of the vascular access seems 
to be predominantly composed of medial 
calcification.10 Most probably, a method 
to evaluate vascular calcifications that 
includes these two types of vascular cal-
cification, intimal and medial calcifica-
tion2,3,5 (E. Honkanen et al., 2008; EDTA 
Congress; Stockholm, Sweden; abstr.), 
should be more appropriate for evaluating 
the global mortality risk. In our opinion, 
there are other limitations in the choice 
of this method to evaluate vascular calci-
fications. One limitation is the exclusion 
of all patients who do not have a vascular 
access, such as peritoneal dialysis patients 
and patients without vascular conditions 
to receive an access. Also, local hemody-
namic factors, unrelated to cardiovascular 
risk, may be associated with development 
of calcifications of the vascular access. The 
presence of calcification in the vascular 
access might have an interesting advantage 
of identifying calcium deposition occur-
ring after initiation of dialysis. However, 
the identification of this phenomenon at 
such a late stage might not be so helpful 
to guide a therapeutic intervention. An 
earlier identification of vascular calcifica-
tions, in predialysis or in incident patients, 
is probably a more intelligent and useful 
approach. Such patients constitute a popu-
lation with elevated risk of rapid calcifica-
tion progression and certainly deserve a 
more aggressive therapeutic approach.
What is the preferable vascular  
calcification screening method?
A method adequate for screening vascu-
lar calcifications should be inexpensive 
and simple to interpret. Any of the plain 
X-ray methods mentioned here for evalu-
ation of vascular calcifications can be easily 
interpreted by the attending physician. 
Another important quality for choosing 
a screening method is a correct balance 
between sensitivity and specificity. Which 
of the methods using plain X-ray for evalu-
ation of vascular calcification is the best? 
For a definitive answer to this question, 
comparative studies in the same population 
will be required and certainly welcome.
In our opinion, all of the methods 
described here that recognize the presence 
of vascular calcification with plain X-ray 
of different vascular territories have been 
demonstrated to be very useful in the eval-
uation of CKD population mortality risk. 
Certainly, the final choice of the method to 
be used in a specific institution should be 
based on the experience and preference of 
the nephrology attending physicians.
What is the importance of screening  
vascular calcifications in dialysis patients?
The identification of dialysis patients with 
calcified vessels and the evaluation of vas-
cular calcification extension could be very 
useful for cardiovascular risk stratification 
and therapeutic guidance. Vascular calci-
fications most likely are multifactorial and 
result from a complex balance between 
inducers and inhibitors. However, at this 
stage of knowledge, we can only interfere 
in a very small number of those factors 
— mainly, alterations of mineral metabo-
lism. Several studies have already dem-
onstrated that vascular calcifications in 
dialysis patients may progress or remain 
stable depending on the control of the 
mineral metabolism alterations, such as 
hyperphosphatemia. Another important 
aspect besides the control of hyperphos-
phatemia per se is the choice of the phos-
phate-binding agent. One should avoid 
the use of calcium-containing phosphate 
binders in patients with calcified vessels.
London et al. demonstrated an associa-
tion between vascular calcifications and 
low bone turnover.7 The same group11 
found a significant interaction between 
dosage of calcium-containing phos-
phate binders and bone activity such 
that calcium load had a significantly 
higher impact on aortic calcifications 
and stiffening in the presence of ady-
namic bone disease. Low-bone-turnover 
status should be prevented, when 
possible, avoiding para thyroid hormone 
Figure 1 | Simple vascular calcification score evaluation. Calcification score is the sum 
of the presence (1) or absence (0) of vascular calcifications in each section. Pelvis score 
(1+1+1+1) = 4 and hands score (1+1+1+1) = 4. Total score is 8.
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oversuppression, and calcium-containing 
binders should be avoided in patients with 
such a condition.11
In summary, vascular calcifications are 
associated with increased mortality in dial-
ysis patients. Different methods can be used 
to identify vascular calcifications in these 
patients. Plain X-ray evaluation of vascular 
calcifications is inexpensive and simple to 
interpret and should be used for the screen-
ing of vascular calcifications. Nephrologists 
have now at their disposal different plain 
X-ray methods to evaluate vascular calcifi-
cations in their CKD patients. The presence 
of vascular calcifications in CKD patients 
constitutes an important alert sign for an 
increased cardiovascular risk. This infor-
mation is important and should serve to 
guide nephrologists in the design of more 
appropriate and aggressive therapeutic 
strategies to control mineral metabolism 
in their patients.
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DRIVE it home:  
making the case for prospective 
economic data collection  
in randomized clinical trials
Eric L. Eisenstein1
Although the results of Pizzi et al. point to the potential economic 
attractiveness of a ferric gluconate treatment strategy, they may not be 
sufficient to change public policy and reimbursement practices. What is 
required is a large, simple trial that will replicate the results of the DRIVE trial 
in a broader population with longer follow-up and a prospectively defined 
economic and quality-of-life study conducted from the societal perspective.
Kidney International (2008) 74, 1507–1509. doi:10.1038/ki.2008.553 
In 1972, Archie Cochrane put forth three 
tests that all medical technologies must 
pass.1 The first test, of efficacy, assesses 
whether the new technology can work 
under ideal circumstances, such as those 
found in a randomized clinical trial. The 
second test, of effectiveness, evaluates 
whether the technology works under usual 
circumstances, such as those found in actual 
practice. And the third test, of efficiency, 
determines whether the new technology is 
worth it—put differently, whether there is 
a proper relationship between the benefits 
derived through the use of the technol-
ogy and the resources it consumes (Figure 
1). While the renal research community 
has demonstrated increasing success in 
answering Cochrane’s first two questions 
with respect to important clinical and pol-
icy issues, it has exhibited less interest in his 
third question. In few areas is the disparity 
between clinical and economic research 
greater than in the appropriate use of epo-
etin alfa for anemia correction in patients 
with kidney disease.
In recent years, our understanding of 
the efficacy and effectiveness of epoetin 
alfa in patients with kidney disease has 
increased substantially. The Cardiovascu-
lar Risk Reduction by Early Anemia Treat-
ment with Epoetin Beta (CREATE) study 
reported that complete correction of ane-
mia in patients with chronic kidney disease 
does not reduce the risk of cardiovascular 
events.2 This message was amplified by the 
Correction of Hemoglobin and Outcomes 
in Renal Insufficiency (CHOIR) study, 
which reported that the use of higher ver-
sus lower target hemoglobin levels is asso-
ciated with increased cardiovascular risk 
with no improvement in quality of life.3 
Subsequently, a secondary analysis from the 
CHOIR study refocused the discussion by 
reporting that patients who achieved their 
hemoglobin targets (whether lower- or 
higher-level) had better cardiovascular out-
comes than those who did not.4 The under-
lying issue was that a greater proportion of 
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